Keziah Cook
Education
Ph.D., economics, Northwestern University; A.B., mathematics, Harvard University
Summary of Experience
Dr. Cook uses economic theories, health care data, and statistical models to support health care policy decisions. She works on cost-effectiveness models, forecasting models, budget impact models, treatment comparisons, burden-of-illness analyses, chart reviews, literature reviews, global value dossiers, and commercial assessments in a range of therapeutic areas. Dr. Cook’s areas of expertise include measuring the clinical quality of health care providers, evaluating the impacts of health care innovations on utilization and health outcomes, comparing the clinical and cost effectiveness of treatment alternatives, and developing economic models of health interventions to guide decision making. She has experience developing cost-effectiveness models for gene therapy in hemophilia A and for a novel cancer screening tool; conducting multiple claims analyses; and supporting US product launches. Prior to joining Analysis Group, Dr. Cook was a health care policy researcher at Acumen LLC, where she directed federal contracts with the Centers for Medicare & Medicaid Services (CMS) to implement components of the Affordable Care Act and support the Medicare program. She supported CMS rulemaking, authored reports to Congress, developed quality-of-care metrics, facilitated audits of Medicare Advantage plans, and assisted state Medicaid agencies, while gaining a deep understanding of Medicare and Medicaid eligibility requirements, benefit design, and reimbursement structure.
-
Real-world treatment, dosing, and discontinuation patterns among patients treated with pegvaliase for phenylketonuria: Evidence from dispensing data
Molecular Genetics and Metabolism Reports, 2022
2022Lah M, Cook K, Aparna Gomes D, Liu S, Tabatabaeepour N, Kirson N, Chen E, Lindstrom K, Bulloch Whitehall K, Van Backle J, Burton BK
HEOR, Epidemiology & Market Access -
Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis
Journal of Managed Care & Specialty Pharmacy, 2021
2021Croteau SE, Cook K, Sheikh L, Chawla A, Sammon J, Solari P, Kim B, Hinds D, Thornburg CD
HEOR, Epidemiology & Market Access -
Effects of metreleptin in patients with lipodystrophy with and without baseline concomitant medication use
Current Medical Research and Opinion, 2021
2021Adamski K, Cook K, Gupta D, Morris E, Tuttle E, Carr E, Cremasco F, Cochran E, Brown RJ
HEOR, Epidemiology & Market Access -
Effects of Metreleptin on Patient Outcomes and Quality of Life in Generalized and Partial Lipodystrophy
Journal of the Endocrine Society, 2021
2021Cook K, Adamski K, Gomes A, Tuttle E, Kalden H, Cochran E, Brown RJ
HEOR, Epidemiology & Market Access -
Healthcare resource utilization and costs associated with postpartum depression among commercially insured households
Current Medical Research and Opinion, 2020
2020Epperson CN, Huang M, Cook K, Gupta D, Chawla A, Greenberg PE, Eldar-Lissai A
HEOR, Epidemiology & Market Access -
Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A
Journal of Medical Economics, 2020
2020Cook K, Forbes SP, Adamski K, Ma JJ, Chawla A, Garrison Jr LP
HEOR, Epidemiology & Market Access -
Following Recent Trends In Affordable Care Act Insurance
Law360, September 9, 2016
2016Chawla A, Cook K
Health Care, HEOR, Epidemiology & Market Access, Insurance